On 18 September 2019, Onxeo released initial results from the first cohort of patients (n=3) in its ongoing Phase Ib DRIIV study with AsiDNA. The three patients had a progressive metastatic cancer (non-small cell lung cancer, triple negative breast cancer, gastric cancer) and were treated with AsiDNA plus carboplatin. No dose-limiting toxicity was observed. Two of the three patients have shown stable disease (RECIST) since the start of the treatment (more than four and five months). While it
19 Sep 2019
Onxeo - First Phase Ib DRIIV results released
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Onxeo - First Phase Ib DRIIV results released
Valerio Therapeutics (ALVIO:PAR) | 0 0 0.0%
- Published:
19 Sep 2019 -
Author:
Dr Jonas Peciulis -
Pages:
2
On 18 September 2019, Onxeo released initial results from the first cohort of patients (n=3) in its ongoing Phase Ib DRIIV study with AsiDNA. The three patients had a progressive metastatic cancer (non-small cell lung cancer, triple negative breast cancer, gastric cancer) and were treated with AsiDNA plus carboplatin. No dose-limiting toxicity was observed. Two of the three patients have shown stable disease (RECIST) since the start of the treatment (more than four and five months). While it